Friday 17 January
SESSION 3 - Vaccine development
Chairs: Eric Tartour and Behazine Combadière
08:30-09:00
- Clinical development of anti-cancer vaccines
Thorbald van Hall (Leiden University Medical Centre Leiden, Netherlands)
09:00-09:30
- Neoantigen Vaccination for Glioblastoma: Getting Personal
David A. Reardon (Dana-Farber Cancer Institute, Boston, USA)
09:30-10:00
- HIV Experimental Medicine studies
Robin Shattock (Imperial College of London, UK)
10:00-10:30
Coffee break
10:30-11:00
- History of RSV vaccine development, current approaches and hurdles
Benoit Callendret (Janssen Vaccines, Leiden, Netherlands)
11:00-11:30
- Bovine respiratory syncytial virus (BRSV) vaccine development
Geraldine Taylor (Pirbright Institute, UK)
11:30-12:30
Posters visit
12:30-14:00
Lunch
14:00-15:30
Selected short oral presentations
- The route of vaccine administration affects early immune responses with consequences on the quality of the long-term specific immunity
Frédéric Martinon (CEA - Université Paris Saclay - Inserm, Fontenay-aux-Roses, FR) - Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination
Eléna Gonçalves (Inserm, Paris, FR) - The delay between immunizations and the route of administration matter to harness innate immune memory induced by vaccine prime
Anne-Sophie Beignon (CEA, Fontenay-aux-Roses, FR) - Identification and validation steps of a novel early biomarker of Neutralizing Antibody response following vaccination
Lucille Adam (Inserm, Paris, FR)
SESSION 4 - Keynote lectures
Chairs: Bertrand Dubois and Camille Locht
15:30-16:10
- B cells in vaccine development
Michel Nussenzweig (Rockefeller University, New York, USA)
16:10-16:50
- The global state of vaccine confidence
Emilie Karafillakis (London School of Hygiene and Tropical Medicine, UK)
16:50-17:30
EpiVax Travel Award for Women Scientists